CAMBRIDGE, Mass.--(BUSINESS WIRE)--Syros Pharmaceuticals (NASDAQ:SYRS), a leader in the development of medicines to control the expression of genes, today announced that it will host a live conference call and webcast at 7:30 a.m. ET on Thursday, November 1, 2018 to report its third quarter 2018 financial results and provide a corporate update.
To access the live conference call, please dial 866-595-4538 (domestic) or 636-812-6496 (international), and refer to conference ID 3988733. A webcast of the call will also be available on the Investors & Media section of the Syros website at www.syros.com. An archived replay of the webcast will be available for approximately 30 days following the presentation.
About Syros Pharmaceuticals
Syros is pioneering the
understanding of the non-coding regulatory region of the genome to
advance a new wave of medicines that control expression of genes. Syros
has built a proprietary platform that is designed to systematically and
efficiently analyze this unexploited region of DNA to identify and drug
novel targets linked to genomically defined patient populations. Because
gene expression is fundamental to the function of all cells, Syros’ gene
control platform has broad potential to create medicines that achieve
profound and durable benefit across a range of diseases. Syros is
currently focused on cancer and monogenic diseases and is advancing a
growing pipeline of gene control medicines. Syros’ lead drug candidates
are SY-1425, a selective RARα agonist in a Phase 2 clinical trial for
genomically defined subsets of patients with acute myeloid leukemia and
myelodysplastic syndrome, and SY-1365, a selective CDK7 inhibitor in a
Phase 1 clinical trial for patients with ovarian and breast cancers. Led
by a team with deep experience in drug discovery, development and
commercialization, Syros is located in Cambridge, Mass.
